{"id":78557,"date":"2026-09-03T17:56:51","date_gmt":"2026-09-03T09:56:51","guid":{"rendered":"https:\/\/flcube.com\/?p=78557"},"modified":"2026-09-03T17:56:51","modified_gmt":"2026-09-03T09:56:51","slug":"nmpa-adds-metomidate-lometomidate-and-solriamfetol-to-psychotropic-drug-schedule-in-three-agency-regulatory-adjustment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78557","title":{"rendered":"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>National Medical Products Administration (NMPA)<\/strong>, together with the Ministry of Public Security and the National Health Commission, jointly issued an announcement adjusting the Schedule of Medicinal <strong>Psychotropic Drugs<\/strong>. Effective October 1, 2026, <strong>metomidate<\/strong> (excluding pharmaceutical preparations containing <strong>metomidate<\/strong> approved for marketing within China), <strong>lometomidate<\/strong> (excluding approved domestic preparations), and <strong>solriamfetol<\/strong> will be added to the schedule \u2014 tightening oversight of three psychoactive compounds while preserving access for legally marketed medicines.<\/p>\n\n\n\n<h2 id=\"h-regulatory-adjustment-at-a-glance\" class=\"wp-block-heading\">Regulatory Adjustment at a Glance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Issuing Authorities<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, Ministry of Public Security, National Health Commission<\/td><\/tr><tr><td>Action Type<\/td><td>Adjustment to the Schedule of Medicinal <strong>Psychotropic Drugs<\/strong><\/td><\/tr><tr><td>Substances Added<\/td><td><strong>Metomidate<\/strong>, <strong>lometomidate<\/strong>, <strong>solriamfetol<\/strong><\/td><\/tr><tr><td>Exclusions<\/td><td>Pharmaceutical preparations containing <strong>metomidate<\/strong> or <strong>lometomidate<\/strong> approved for marketing within China<\/td><\/tr><tr><td>Effective Date<\/td><td>October 1, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-scope-amp-implementation-notes\" class=\"wp-block-heading\">Scope &amp; Implementation Notes<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted scheduling:<\/strong> The adjustment schedules the raw substances <strong>metomidate<\/strong>, <strong>lometomidate<\/strong>, and <strong>solriamfetol<\/strong> as medicinal <strong>psychotropic drugs<\/strong>, subjecting them to China&#8217;s controlled\u2011substance management framework<\/li>\n\n\n\n<li><strong>Marketing carve\u2011out:<\/strong> Domestically approved pharmaceutical preparations containing <strong>metomidate<\/strong> or <strong>lometomidate<\/strong> are explicitly excluded, ensuring continuity of supply for legitimate clinical use<\/li>\n\n\n\n<li><strong>Three\u2011agency coordination:<\/strong> Joint issuance by the drug regulator, public security authority, and health commission reflects the combined oversight model applied to psychotropic substances in China \u2014 covering regulation, enforcement, and clinical governance<\/li>\n\n\n\n<li><strong>Implementation runway:<\/strong> The roughly one\u2011month interval between announcement and the October 1, 2026 effective date provides industry stakeholders time to align manufacturing, distribution, and prescription practices with the new schedule<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tighter control of psychoactive substances:<\/strong> Adding <strong>metomidate<\/strong>, <strong>lometomidate<\/strong>, and <strong>solriamfetol<\/strong> to the <strong>psychotropic drug<\/strong> schedule strengthens supervision against misuse while formalizing their status within the medicinal framework<\/li>\n\n\n\n<li><strong>Continuity for approved products:<\/strong> The explicit exclusion of domestically approved preparations shields incumbent manufacturers of <strong>metomidate<\/strong>\u2011 and <strong>lometomidate<\/strong>\u2011containing medicines from supply disruption, though compliance and traceability requirements may still increase<\/li>\n\n\n\n<li><strong>Import and development implications:<\/strong> For <strong>solriamfetol<\/strong> \u2014 a wakefulness\u2011promoting agent approved in overseas markets \u2014 scheduling status becomes a key consideration for any future China registration strategy<\/li>\n\n\n\n<li><strong>Policy signal:<\/strong> The adjustment continues China&#8217;s pattern of proactively updating psychotropic schedules in response to emerging substance\u2011use risks, aligning medicinal access with public\u2011safety enforcement<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief describes a regulatory policy announcement and its potential industry implications. Interpretation of scheduling requirements and their commercial effects involves uncertainty; companies should consult the official joint announcement from the <strong>NMPA<\/strong>, Ministry of Public Security, and National Health Commission for definitive requirements. No investment decision should be made solely on the basis of this brief.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[14],"class_list":["post-78557","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the National Health Commission, jointly issued an announcement adjusting the Schedule of Medicinal Psychotropic Drugs. Effective October 1, 2026, metomidate (excluding pharmaceutical preparations containing metomidate approved for marketing within China), lometomidate (excluding approved domestic preparations), and solriamfetol will be added to the schedule \u2014 tightening oversight of three psychoactive compounds while preserving access for legally marketed medicines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78557\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78557\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T09:56:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78557#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78557\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment\",\"datePublished\":\"2026-09-03T09:56:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78557\"},\"wordCount\":424,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78557#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78557\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78557\",\"name\":\"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-03T09:56:51+00:00\",\"description\":\"The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the National Health Commission, jointly issued an announcement adjusting the Schedule of Medicinal Psychotropic Drugs. Effective October 1, 2026, metomidate (excluding pharmaceutical preparations containing metomidate approved for marketing within China), lometomidate (excluding approved domestic preparations), and solriamfetol will be added to the schedule \u2014 tightening oversight of three psychoactive compounds while preserving access for legally marketed medicines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78557#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78557\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78557#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the National Health Commission, jointly issued an announcement adjusting the Schedule of Medicinal Psychotropic Drugs. Effective October 1, 2026, metomidate (excluding pharmaceutical preparations containing metomidate approved for marketing within China), lometomidate (excluding approved domestic preparations), and solriamfetol will be added to the schedule \u2014 tightening oversight of three psychoactive compounds while preserving access for legally marketed medicines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78557","og_locale":"en_US","og_type":"article","og_title":"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=78557","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-03T09:56:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78557#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78557"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment","datePublished":"2026-09-03T09:56:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78557"},"wordCount":424,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78557#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78557","url":"https:\/\/flcube.com\/?p=78557","name":"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-03T09:56:51+00:00","description":"The National Medical Products Administration (NMPA), together with the Ministry of Public Security and the National Health Commission, jointly issued an announcement adjusting the Schedule of Medicinal Psychotropic Drugs. Effective October 1, 2026, metomidate (excluding pharmaceutical preparations containing metomidate approved for marketing within China), lometomidate (excluding approved domestic preparations), and solriamfetol will be added to the schedule \u2014 tightening oversight of three psychoactive compounds while preserving access for legally marketed medicines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78557#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78557"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78557#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three\u2011Agency Regulatory Adjustment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78557"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78557\/revisions"}],"predecessor-version":[{"id":78560,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78557\/revisions\/78560"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}